Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians

Pharmacogenetics

Volumn 8, Issue 4, 1998, Pages 325-333

  Droll, Kurt ^a,b   Bruce Mensah, Kofi ^a,b   Victoria Otton, S ^a,b   Gaedigk, Andrea ^c   Sellers, Edward M ^a,b,d,e   Tyndale, Rachel F ^a,b,d,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP2D6; Cytochrome; Debrisoquine; Dextromethorphan; P450; Sparteine

Indexed keywords

DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; KOFFEX; QUINIDINE; SPARTEINE; SPARTEINE SULFATE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CAUCASIAN; CHINESE; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME SPECIFICITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; METABOLIC RATE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DEXTROMETHORPHAN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; SPARTEINE; SUBSTRATE SPECIFICITY;

LEPUS;

EID: 0031828554     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199808000-00006     Document Type: Article

References (33)

1. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of DB in an Ethopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-446.
2. Alvan G, Bechtel P, Iselius L, Gunder-Remy U. Hydroxylation polymorphisms of DB and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-537.
3. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of DB and S-mephenytoin. Clin Pharmacol Ther 1992: 51: 388-397.
4. Bertilsson L, Meese CO, Yue QY, Dahl ML. Ingelman-Sundberg M, Johansson I, et al. Quinidine inhibition of DB S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Pharmacogenetics 1993; 3:94-100.
5. Brinn R, Brosen K, Gram LF, Haghfelt T, Otton SV. SP oxidation is practically abolished in quinidine treated patients. Br J Clin Pharmacol 1986; 22:194-197.
6. Du YL, Lou YQ. Polymorphism of DB 4-hydroxylation and family studies of poor metabolizers in Chinese population. Acta Pharmacologica Sinica 1990: 11:7-10.
7. Eichelbaum M, Bertilsson L, Säwe J, Zekorn C. Polymorphic oxidation of SP and DB: related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31:184-186.
8. Eichelbaum M, Woolhouse NM. Inter-ethnic difference in SP oxidation among Ghanaians and Germans. Eur J Clin Pharmacol 1985; 28:79-83.
9. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of DB oxidation in a white British population. J Med Genet 1980; 17:102-105.
10. Ferguson GA, Takane Y. Statistical analysis in psychology and education. 6th ed. New York: McGraw-Hill: 1989.
11. Heim M, Meyer UA. Genotyping of poor metabolizers of DB by allele-specific PCR amplification. Lancet 1990; 336:529-532.
12. Inaba T, Otton SV, Kalow W, DB hydroxylation capacity: problems of assessment in two populations. Clin Pharmacol Ther 1981; 29:218-223.
13. Inaba T, Tyndale RF, Mahon WA. Quinidine: potent inhibition of SP and DB oxidation in vivo. Br J Clin Pharmacol 1986; 22:199-200.
14. Johansson I, Yue QY, Dahl ML, Heim M, Säwe J, Bertilsson L, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of DB and codeine. Eur J Clin Pharmacol 1991; 40:553-556.
15. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese Cytochrome P450D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for DB hydroxylation. Mol Pharmacol 1994; 46:452-459.
16. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet 1982; 7:373-400.
17. Kalow W, Bertilsson L. Interethnic factors affecting drug response. Adv Drug Res 1994; 25:1-53.
18. Lee EJD, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994; 37:605-607.
19. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Wood HF. Evidence for a dissociation of SP, DB and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2:89-92.
20. Llerena A, Herraiz AG, Cobaleda J, Johansson I, Dahl ML, DB and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993; 54:606-611.
21. Lou YC, Liu Y, Bertilsson L, Sjöqvist F. Low frequency of slow DB hydroxylation in a native Chinese population. Lancet 1987; 2:852-853.
22. Malcolm SL, Marten TR. Determination of DB and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry. Anal Chem 1976; 48:807-809.
23. Masimirembwa C, Hasler J, Bertilsson L, Johansson I, Ekberg O. Ingelman-Sundberg M. Phenotype and genotype analysis of DB hydroxylase (CYT2D6) in a black Zimbabwean population: reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996a; 51: 117-122.
24. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished DB hydroxylase activity. Br J Clin Pharmacol 1996b; 42:13-719.
25. Matsunaga E, Zeugin T, Zanger UM, Aoyama T, Meyer UA, Gonzalez FJ. Sequence requirement for cytochrome P450IIDI catalytic activity. A single amino acid change specifically decreases Vmax of the enxyme for bufuralol but not DB hydroxylation. J Biol Chem 1990; 265:17197-17201.
26. Olson CL. Statistics: making sense of data. Toronto: Allyn and Bacon Inc: 1988.
27. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53:401-409.
28. Schmid B, Bircher J, Preisig R, Küpfer A. Polymorphic DEX metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
29. Simooya OO, Njunju E, Rostami Hodjegan A, Lennard MS, Tucker GT, DB and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 1993; 3:205-208.
30. Sommers De K, Moncrieff J, Avenant J. Non-correlation between DB and metoprolol polymorphisms in the Venda. Human Toxicol 1989; 8:365-368.
31. Vinks A, Inaba T, Otton SV, Kalow W. SP metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982; 31:23-29.
32. Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL. Dissociation of co-regulatory control of debrisoquin/phenformin and SP oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37:512-521.
33. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. DEX: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992; 52:47-655.